ClinicalTrials.gg
CompletedNCT02652624Updated Mar 4, 2020Results posted

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

A Phase 3 interventional study of E/C/F/TAF and E/C/F/TDF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 56 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
472
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF), or atazanavir (ATV) + ritonavir (RTV) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically suppressed HIV-1 infected women.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

Medically stable -1 infected women who meet the following criteria:

  • Completion of the Week 48 open-label extension (OLE) visit or any post Week 48 OLE visits in Gilead-sponsored study GS-US-236-0128, or Completion of the Week 96 visit or any post Week 96 visits in Gilead-sponsored study GS-US-292-0109 or completion of the Week 144 visit or any post Week 144 visits in Gilead sponsored studies GS-US-292-0104 or GS-US-292-0111.
  • Currently on a stable antiretroviral regimen consisting of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF continuously for ≥ 12 consecutive weeks preceding the Screening visit
  • Documented plasma HIV-1 RNA levels \< 50 copies/mL for ≥ 12 weeks preceding the Screening visit. After reaching HIV-1 RNA \< 50 copies/mL, single values of HIV-1 RNA

    ≥ 50 copies/mL followed by re-suppression to \< 50 copies/mL is allowed

  • HIV-1 RNA \<50 copies/mL at screening
  • Estimated (eGFR) ≥ 50 mL/min (≥ 0.83 mL/sec) according to the formula at the Screening visit

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
472 participants (actual)

Study arms

  • Experimental
    B/F/TAF

    Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.

    Drug: B/F/TAF

  • Active comparator
    Baseline Regimen

    Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.

    Drug: E/C/F/TAF · Drug: E/C/F/TDF · Drug: ATV · Drug: RTV · Drug: FTC/TDF

  • Experimental
    Extension Phase

    Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks.

    Drug: B/F/TAF

Interventions

  • DrugE/C/F/TAF

    Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    150/150/200/10 mg FDC tablet administered orally once daily with food

    Also known as: Genvoya®

  • DrugE/C/F/TDF

    150/150/200/300 mg FDC administered orally once daily with food

    Also known as: Stribild®

  • DrugATV

    ATV 300 mg capsules administered orally once daily with food

    Also known as: Reyataz®

  • DrugRTV

    RTV 100 mg tablets administered orally once daily with food

    Also known as: Norvir®

  • DrugFTC/TDF

    200/300 mg tablet administered orally once daily with food

    Also known as: Truvada®

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    50/200/25 mg FDC tablet administered orally once daily without regard to food

    Also known as: Biktarvy®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  2. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

07

Results

Posted Nov 2, 2018

Participant flow

Participants were enrolled at study sites in the United States, Russian Federation, Thailand, Dominican Republic, and Uganda. The first participant was screened on 19 February 2016. The last study visit occurred on 26 November 2018.

Randomized Phase
Participant flow — Randomized Phase
MilestoneB/F/TAFStay on Baseline Regimen (SBR)
Started234236
Completed231231
Not completed35
Withdrew: Pregnancy31
Withdrew: Investigator's discretion02
Withdrew: Death01
Withdrew: Lost to follow-up01
Extension Phase
Participant flow — Extension Phase
MilestoneB/F/TAFStay on Baseline Regimen (SBR)
Started231228
Completed227224
Not completed44
Withdrew: Lost to follow-up31
Withdrew: Pregnancy11
Withdrew: Adverse event01
Withdrew: Withdrew consent01

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFStay on Baseline Regimen
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm1.71.7
Statistical analysis
  • B/F/TAF vs Stay on Baseline Regimen · Difference in percentages: 0.0 · 95.001% CI -2.9 to 2.9The difference in percentages between treatment groups and their 95.001% confidence intervals (CI) were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
  • B/F/TAF vs Stay on Baseline Regimen · Fisher Exact · p = 1.00
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFStay on Baseline Regimen
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm95.795.3
Statistical analysis
  • B/F/TAF vs Stay on Baseline Regimen · Difference in percentages: 0.4 · 95.001% CI -3.7 to 4.5The difference in percentages between treatment groups and their 95.001% CIs were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
  • B/F/TAF vs Stay on Baseline Regimen · Fisher Exact · p = 1.00
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLB/F/TAFStay on Baseline Regimen
Change From Baseline in CD4+ Cell Count at Week 4829 ± 159.426 ± 170.3
Statistical analysis
  • B/F/TAF vs Stay on Baseline Regimen · ANOVA · p = 0.84 · Difference in least square means: 3 · 95% CI -27 to 34Difference in least squares means and its 95% CI were from ANOVA model with treatment group as a fixed effect in the model.

Adverse events

Collected over First dose date to last dose date (maximum duration: 128.4 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B/F/TAF (Randomized Phase)0/234 (0%)7/234 (3%)61/234 (26.1%)
Stay on Baseline Regimen (Randomized Phase)0/236 (0%)9/236 (3.8%)47/236 (19.9%)
Extension Phase B/F/TAF From B/F/TAF0/231 (0%)8/231 (3.5%)52/231 (22.5%)
Extension Phase B/F/TAF From Stay on Baseline Regimen1/228 (0.4%)10/228 (4.4%)41/228 (18%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventB/F/TAF (Randomized Phase)Stay on Baseline Regimen (Randomized Phase)Extension Phase B/F/TAF From B/F/TAFExtension Phase B/F/TAF From Stay on Baseline Regimen
ColitisGastrointestinal disorders0/2342/2360/2310/228
Acute myocardial infarctionCardiac disorders0/2340/2360/2311/228
Non-cardiac chest painGeneral disorders0/2340/2360/2311/228
Cholecystitis acuteHepatobiliary disorders0/2340/2360/2311/228
Viral infectionInfections and infestations0/2340/2360/2311/228
Joint dislocationInjury, poisoning and procedural complications0/2340/2360/2311/228
HyperglycaemiaMetabolism and nutrition disorders0/2340/2360/2311/228
OsteoarthritisMusculoskeletal and connective tissue disorders0/2341/2360/2311/228
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2340/2360/2311/228
Foetal deathPregnancy, puerperium and perinatal conditions0/2340/2360/2311/228
Most frequent other events
Most frequent other events
EventB/F/TAF (Randomized Phase)Stay on Baseline Regimen (Randomized Phase)Extension Phase B/F/TAF From B/F/TAFExtension Phase B/F/TAF From Stay on Baseline Regimen
NasopharyngitisInfections and infestations18/23415/23619/23113/228
Upper respiratory tract infectionInfections and infestations15/23414/23619/23115/228
Urinary tract infectionInfections and infestations16/2344/2368/2315/228
HeadacheNervous system disorders12/23413/23613/2318/228
Vulvovaginal candidiasisInfections and infestations12/2349/2369/2319/228

Baseline characteristics

The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)B/F/TAFStay on Baseline RegimenTotal
Mean40 ± 9.540 ± 9.140 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)B/F/TAFStay on Baseline RegimenTotal
Female234236470
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)B/F/TAFStay on Baseline RegimenTotal
Hispanic or Latino363874
Not Hispanic or Latino198198396
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFStay on Baseline RegimenTotal
Asian4854102
Black9183174
White6667133
Other293261
Region of Enrollment
Region of Enrollment(Participants)B/F/TAFStay on Baseline RegimenTotal
United States363672
Dominican Republic283058
Uganda6562127
Thailand4754101
Russia5854112
HIV-1 RNA Category
HIV-1 RNA Category(Participants)B/F/TAFStay on Baseline RegimenTotal
< 50 copies/mL234233467
≥ 50 copies/mL033
CD4 Cell Count
CD4 Cell Count(cells/µL)B/F/TAFStay on Baseline RegimenTotal
Mean712 ± 268.1738 ± 268.4725 ± 268.3
CD4 Cell Count Category
CD4 Cell Count Category(Participants)B/F/TAFStay on Baseline RegimenTotal
≥ 50 to < 200 cells/µL112
≥ 200 to < 350 cells/µL10919
≥ 350 to < 500 cells/µL332558
≥ 500 cells/µL190201391

1 further baseline measures are reported on the registry.

08

Study locations

56 sites
  • Stamford, Connecticut 6902, United States
  • Washington, District of Columbia 20009, United States
  • Washington, District of Columbia 20037, United States
  • Fort Lauderdale, Florida 33308, United States
  • Fort Pierce, Florida 34982, United States
  • Miami, Florida 33133, United States
  • Miami, Florida 33136, United States
  • Orlando, Florida 32803-1851, United States
  • Tampa, Florida 33607, United States
  • Tampa, Florida 33614, United States
  • West Palm Beach, Florida 33401, United States
  • Atlanta, Georgia 30308, United States
  • Decatur, Georgia 30033, United States
  • Macon, Georgia 31201, United States
  • Savannah, Georgia 31401, United States
  • Springfield, Massachusetts 01105, United States
  • Saint Louis, Missouri 63110, United States
  • Newark, New Jersey 07102, United States
  • Bronx, New York 10467, United States
  • Great Neck, New York 11021, United States
  • Charlotte, North Carolina 28207, United States
  • Durham, North Carolina 27710, United States
  • Huntersville, North Carolina 28078, United States
  • Bellaire, Texas 77401, United States
  • Dallas, Texas 75208, United States
  • Dallas, Texas 75219, United States
  • Fort Worth, Texas 76104, United States
  • Harlingen, Texas 78550, United States
  • Houston, Texas 77004, United States
  • Santo Domingo, 10514, Dominican Republic
  • Santo Domingo, Dominican Republic
  • San Juan, 00909-1711, Puerto Rico
  • Barnaul, 656010, Russian Federation
  • Ekaterinburg, 620102, Russian Federation
  • Irkutsk, 664043, Russian Federation
  • Khabarovsk, 680031, Russian Federation
  • Koltsovo, 630559, Russian Federation
  • Krasnodar, 350015, Russian Federation
  • Krasnoyarsk, 660049, Russian Federation
  • Lipetsk, 398043, Russian Federation
  • Moscow, 105275, Russian Federation
  • Moscow, 129110, Russian Federation
  • Nizhniy Novgorod, 603950, Russian Federation
  • Saint Petersburg, 190103, Russian Federation
  • Saint Petersburg, 196645, Russian Federation
  • Saint-Petersberg, 190020, Russian Federation
  • Saint-Petersburg, 191167, Russian Federation
  • Volgograd, 400010, Russian Federation
  • Voronezh, 394065, Russian Federation
  • Bangkok, 10330, Thailand
  • Bangkok, 10400, Thailand
  • Bangkok, 10700, Thailand
  • Chiang Mai, 50200, Thailand
  • Khon Kaen, 40002, Thailand
  • Nonthaburi, 11000, Thailand
  • Kampala, Uganda
09

References and documents

Publications

  • Kityo C, Hagins D, Koenig E, Avihingsanon A, Chetchotisakd P, Supparatpinyo K, Gankina N, Pokrovsky V, Voronin E, Stephens JL, DeJesus E, Wang H, Acosta RK, Cao H, Quirk E, Martin H, Makadzange T. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):321-328. doi: 10.1097/QAI.0000000000002137. PubMed 31609930 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Oct 2017, 19 months.

Results were first posted in Nov 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2016
First posted
Jan 12, 2016
StartActual
Feb 19, 2016
Primary completionActual
Oct 9, 2017
CompletionActual
Nov 26, 2018
Results first posted
Nov 2, 2018
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02652624
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 12, 2016
Start date
Feb 19, 2016
Primary completion
Oct 9, 2017
Completion
Nov 26, 2018
Results posted
Nov 2, 2018
Last update
Mar 4, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Bictegravir

Start the discussion